Compare · NN vs TMO
NN vs TMO
Side-by-side comparison of NextNav Inc. (NN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NN and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $174.52B, about 60.9x NN ($2.87B).
- Over the past year, NN is up 70.7% and TMO is up 14.9% - NN leads by 55.7 points.
- Both names hit the wire about 17 times in the past 4 weeks.
- TMO has more recent analyst coverage (25 ratings vs 6 for NN).
- Company
- NextNav Inc.
- Thermo Fisher Scientific Inc
- Price
- $21.02-2.62%
- $469.56-0.67%
- Market cap
- $2.87B
- $174.52B
- 1M return
- +7.79%
- -1.03%
- 1Y return
- +70.66%
- +14.92%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 17
- 17
- Recent ratings
- 6
- 25
NextNav Inc.
Spartacus Acquisition Corporation intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Duluth, Georgia.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest NN
- CEO, President and Director Sorond Mariam sold $1,391,426 worth of shares (69,853 units at $19.92) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 1,244,495 units (SEC Form 4) (tax liability)
- NextNav Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- NextNav Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits
- NextNav Announces Redemption of Public Warrants
- Director Carano Bandel L was granted 7,550 shares, increasing direct ownership by 4% to 188,568 units (SEC Form 4)
- Director Marcus Jonathan Anthony was granted 7,550 shares, increasing direct ownership by 24% to 38,444 units (SEC Form 4)
- Director Hook Lisa was granted 7,550 shares, increasing direct ownership by 166% to 12,095 units (SEC Form 4)
- Director Howe Alan B was granted 7,550 shares, increasing direct ownership by 2% to 336,661 units (SEC Form 4)
- Director Howard Hugh Wyman Iii was granted 7,550 shares, increasing direct ownership by 57% to 20,704 units (SEC Form 4)
- Director Palmer Nicola was granted 7,550 shares, increasing direct ownership by 25% to 38,327 units (SEC Form 4)
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)